Earnings call transcript: Progyny Q2 2025 beats EPS forecasts with strong growth

Progyny Inc. (PGNY) reported strong Q2 2025 results, with adjusted EPS of $0.48 significantly surpassing the $0.16 forecast and revenue reaching $332.9 million, a 9.5% year-over-year increase. Despite this substantial beat and a 16% rise in gross profit, the stock declined 1.83% in aftermarket trading, potentially due to investor profit-taking or future growth concerns. The company provided an optimistic full-year revenue guidance of $1.235 billion to $1.270 billion, driven by continued client expansion, new product offerings like pelvic floor therapy, and a new partnership with Amazon's Health Benefits Connector program, all supported by a robust balance sheet.

Analysis

Progyny Inc. (PGNY) delivered a strong second-quarter performance, highlighted by an adjusted EPS of $0.48 that surpassed consensus forecasts of $0.16 by 200%. Revenue grew 9.5% year-over-year to $332.9 million, also beating expectations, driven by an expansion in the client base and covered lives. Operational efficiency improved, with gross profit increasing 16% and gross margin expanding to 23.7% from 22.5% in the prior-year period. Despite these robust results and an upward revision to its full-year guidance, the stock price fell 1.83% in aftermarket trading, indicating a potential disconnect between fundamental performance and market sentiment, possibly attributable to profit-taking or a nuanced interpretation of the forward-looking sales commentary.

The company's outlook remains positive, with full-year revenue guidance raised to between $1.235 billion and $1.270 billion. Critically, when excluding a large former client, the underlying business demonstrates stronger momentum, with projected full-year core revenue growth between 15.1% and 18.5%. Management commentary on the 2026 selling season revealed that while the new business pipeline started slowly, it is now comparable to the prior year. Early client commitments show similar expected revenue but fewer covered lives due to a demographic mix skewed towards higher-utilization industries, a factor management expects to normalize as the sales season progresses. Strategic initiatives, including the integration of Benefit Bump, expansion of global services, and a new partnership with Amazon's Health Benefits Connector, are positioned to support long-term growth.

Key Decisions for Investors

• Investors should analyze the divergence between Progyny's strong Q2 earnings beat and raised guidance versus the negative aftermarket stock reaction, which may signal a potential valuation opportunity.
• It is critical to monitor the progression of the 2026 selling season, paying close attention to whether the client mix and covered lives normalize as management anticipates.
• Focus on the core revenue growth of 15-18% projected for the full year, excluding the terminated large client, as this is a more accurate gauge of the company's underlying business momentum.
• Evaluate the company's ability to successfully upsell new offerings, such as expanded global services and pelvic floor therapy, as execution in these adjacent markets is key to sustaining long-term growth beyond the primary fertility segment.